Law Firm Files Securities Class Action Against Quantum Biopharma Over Alleged Market Manipulation

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Law firm sues Quantum Biopharma for alleged market manipulation through spoofed sell orders, claiming defendants artificially suppressed stock price from 2021-2025.

Law Firm Files Securities Class Action Against Quantum Biopharma Over Alleged Market Manipulation

The Portnoy Law Firm has initiated a class action lawsuit targeting Quantum Biopharma, Ltd. on behalf of investors who acquired company securities during a nearly five-year period spanning January 6, 2021 through October 15, 2025. The legal filing alleges that defendants engaged in coordinated market manipulation tactics involving spoofed sell orders—a practice wherein false trading signals are placed to create misleading market conditions.

According to the complaint, the alleged manipulation scheme was designed to artificially suppress the company's stock price, enabling defendants to acquire shares at depressed valuations. The lawsuit contends that legitimate investors were simultaneously deceived into divesting their holdings at artificially diminished prices, resulting in substantial losses during the alleged manipulation period.

The case represents one of several enforcement actions targeting market manipulation practices in the equities markets. Shareholders who believe they sustained losses during the specified timeframe may be eligible to participate in the class action. The litigation is ongoing, and no determinations regarding liability or damages have been made at this stage.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 17

Related Coverage

GlobeNewswire Inc.

Plug Power Faces Class Action Over DOE Loan Claims as April Deadline Looms

Plug Power faces class action lawsuit alleging false statements about DOE loans and hydrogen facilities. Investors have until April 3, 2026 to apply as lead plaintiffs.

PLUG
GlobeNewswire Inc.

BlackRock TCP Capital Hit by Class Action Over $19B NAV Collapse

BlackRock TCP Capital faces class action lawsuit after 19% NAV decline and 12.97% stock plunge. Investors must act by April 6 deadline.

TCPC
GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
GlobeNewswire Inc.

Class Action Lawsuit Filed Against China Liberal Education Over Alleged $300M Pump-and-Dump Scheme

Class action lawsuit filed against China Liberal Education Holdings for alleged pump-and-dump scheme coordinating with scammers, resulting in $300M+ investor losses.

CLEUF
GlobeNewswire Inc.

METC Faces Class Action Over Brook Mine Claims; Lead Plaintiff Deadline Set for March 31

Ramaco Resources faces class action lawsuit over alleged false Brook Mine operational claims, with lead plaintiff deadline set for March 31, 2026.

METCMETCBMETCI
GlobeNewswire Inc.

Disc Medicine Stock Collapses on FDA Rejection; Law Firm Probes Securities Fraud

Pomerantz LLP investigates Disc Medicine ($IRON) for potential securities fraud after FDA rejected bitopertin drug application, triggering consecutive stock declines totaling over 28%.

IRON